Clinical trials: Tumor Immune Microenvironment
Hepatocellular Carcinoma, Non-small Cell Lung Cancer Metastatic
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
This study is being done to look at how effective the drug, atezolizumab, with or without the drug bevacizumab, is for people with inoperable liver cancer or non-small lung cancer that has spread to the liver.
- Conditions
- Hepatocellular Carcinoma, Non-small Cell Lung Cancer Metastatic, Liver Metastases
- Trial name
- NCT04563338
- Testing
- Atezolizumab, Bevacizumab
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
Ovarian Cancer
The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical Significance
The aim of this study is to evaluate the insulin-like growth factor (IGF) axis involvement in the immune tumor microenvironment in ovarian cancer.
- Trial name
- NCT03846856
- Testing
- Biopsy
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Hillel Yaffe Medical Center
Advanced Biliary Tract Cancer
GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）
To evaluate the efficacy and immune microenvironment changes in treatment-naïve advanced biliary tract cancer (BTC) patients receiving first-line standard therapy with gemcitabine/cisplatin (GemCis) combined with PD-1/PD-L1…
- Trial name
- BTC-IM-1 (NCT06988592)
- Testing
- GemCis plus PD-1/PD-L1 inhibitor
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Immune Microenvironment, Luminal A
Tumor Immune Mechanism of Axillary Lymph Node Metastasis in Early Luminal Type A Breast Cancer
Luminal type A breast cancer is a type with good clinical prognosis, and the proportion of lymph node metastasis is low, but a small number of patients have more lymph node metastasis when the primary tumor is very small, and the…
- Conditions
- Immune Microenvironment, Luminal A, Lymph Node Metastases
- Trial name
- NCT04322331
- Testing
- no intervention
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University People's Hospital
Hepatocellular Carcinoma
Prospective Cohort Study on the Clinical Trajectory of Resected Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 6th most common cancer in the world but the 2nd most important cause of cancer death. Because of its highly heterogeneous nature, the current approach to identifying druggable targets have…
- Trial name
- PLANET (NCT03267641)
- Where
- 6 sites in Malaysia, Philippines and 2 more
- Volunteers
- 86 people
- Sponsor
- National Cancer Centre, Singapore
Cutaneous Squamous Cell Carcinoma (CSCC)
Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans, it exhibits a high tumor mutational burden and is more common in immunocompromised patients, which aimed to explore the impact of…
- Trial name
- NGF-GRACE (NCT07064330)
- Testing
- Cemiplimab
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
Multiple Myeloma
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation
This randomized phase II trial compares how well adding XMO2 Filgrastim (Granix) to melphalan before a stem cell transplant works in treating patients with multiple myeloma.
- Trial name
- NCT02112045
- Testing
- Granix, High dose melphalan (HDR), Autologous Stem Cell Transplant (ASCT)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Washington University School of Medicine
MACE, Arrhythmia, Pericardial Effusion and Survival
Cardiac Safety Management and Immune Microenvironment Changes After Thoracic Radiotherapy: A Prospective Observational Study
The goal of this observational study is to learn about cardiac safety monitoring after thoracic radiotherapy in adults with thoracic tumors.
- Trial name
- NCT07669493
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Hebei Medical University Fourth Hospital
Solid Tumors, Metastatic Cancer to Liver
Organ-Specific Differences in Immunotherapy Response Among Metastatic Cancer Patients
This study examines how tumors in different metastatic organs respond to immune checkpoint inhibitor (ICB) therapy in real-world clinical practice.
- Conditions
- Solid Tumors, Metastatic Cancer to Liver, Metastatic Cancer to the Bone, Metastatic Cancer to the Lung
- Trial name
- NCT07631611
- Where
- China
- Volunteers
- 938 people
- Sponsor
- Wenlong Zhong, MD
Lung Neoplasms, Non Small Cell Lung Cancer
ERICA-02 Study : Impact of Physical Exercise on the Tumor Immune Microenvironment in Patients Treated With Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer
Recent advances combining chemotherapy and immunotherapy before surgery have significantly improved outcomes for patients with resectable non-small cell lung cancer (NSCLC).
- Trial name
- ERICA-02 (NCT07786909)
- Testing
- Physical activity recommendations, Physical Activity (PA) Intervention
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Leon Berard
Acute Lymphoid Leukemia, Acute Myeloid Leukemia in Children
Study of the Medullary Microenvironment in Acute Childhood Leukemia
Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child.
- Trial name
- MILA (NCT05792007)
- Testing
- Biological sampling in patients, Biological sampling in control patients
- Where
- 3 sites in France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Pancreatic Adenocarcinoma
Multimodal Deep Learning Model Predicts Pancreatic Cancer Prognosis
This study describes the development and validation of a deep learning prediction model, which extracts deep learning features from preoperative enhanced CT scans and analyzes postoperative pathological specimens of pancreatic…
- Trial name
- NCT06760234
- Testing
- No Interventions
- Where
- China
- Volunteers
- 247 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Endometrium Cancer, Tumor Infiltration
Tumor-Infiltrating Lymphocytes in Endometrial Cancer
Endometrial cancer (EC) is a leading cancer among women globally. The tumor microenvironment in EC is characterized by complex interactions between cancer cells and immune components.
- Trial name
- NCT06976333
- Testing
- Tumor-infliltrating lymphocyte (TIL) percentage, Grey level co-occurrence matrix (GLCM), Fractal dimension (FD)
- Where
- Poland
- Volunteers
- 52 people
- Sponsor
- Jagiellonian University
Advanced Melanoma
Naltrexone and Propranolol Combined With Immunotherapy
Various forms of stress can promote cancer development and growth and negatively impact the immune system's response to tumors. Beta-adrenergic and opioid receptors co-exist in many cells including immune cells and are integral…
- Trial name
- NCT05968690
- Testing
- Propranolol, Naltrexone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sarah Weiss
Hepatocellular Carcinoma
DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab
Part I (Clinical trial setting): A single-arm phase II study to investigate the efficacy of neoadjuvant atezolizumab (T) + bevacizumab (A) in patients with potentially resectable BCLC stage B/C or high risk resectable…
- Trial name
- DYNAMIC (NCT04954339)
- Testing
- Aatezolizumab plus Bevacizumab
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Tae Won Kim
Neoplasms, Immunotherapy
IMMUNO-FIT Observational Study
This observational study will investigate how immunotherapy affects physical fitness, quality of life, and treatment tolerance in adults with solid cancers.
- Conditions
- Neoplasms, Immunotherapy, Physical Fitness, Quality of Life
- Trial name
- NCT07354971
- Testing
- Observational Study - No Study Intervention
- Where
- United Kingdom
- Volunteers
- 67 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC)
Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer
Bladder cancer is a significant global health issue. When the cancer spreads into the muscle layer of the bladder (muscle-invasive bladder cancer), a common treatment is the surgical removal of the bladder (radical cystectomy).
- Conditions
- Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC), Bladder Cancer, Muscle-Invasive Urothelial Bladder Carcinoma
- Trial name
- NCT07525349
- Volunteers
- 100 people
- Sponsor
- Assiut University
Locally Advanced Gastric Cancer
Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer
This is a single-arm, open, exploratory clinical study to evaluate the efficacy of carrelizumab (PD-1) combined with chemotherapy (SOX/XELOX) as neoadjuvant therapy and to observe the changes of tumor immune microenvironment in…
- Trial name
- NCT05545436
- Testing
- Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Lung Neoplasms, Tumor Immune Microenvironment
Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study
This prospective observational study aims to evaluate whether immune profiles of T-cell subsets in bronchoalveolar lavage fluid can complement tumor PD-L1 expression, assessed by immunohistochemistry in tumor tissue specimens, in…
- Trial name
- NCT07331701
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Mycosis Fungoides, Sezary Syndrome
Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.
A translational study for identification of prognostic and treatment-predictive biomarkers in Mycosis fungoides and Sézary syndrome.
- Trial name
- BIO-MUSE (NCT04904146)
- Testing
- Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.
- Where
- Sweden
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Lund University Hospital